FDA Commissioner's National Priority Voucher (CNPV) program versus Priority Review Voucher (PRV)

FDA created a new voucher program called "Commissioner's National Priority Voucher (CNPV) Pilot Program" to accelerate Drug Review for Companies Supporting U.S. National Interests. The CNPV pilot program offers an unprecedented opportunity to reduce drug and biological product application or efficacy supplement (ES) review times from 10-12 months to just 1-2 months. Announced in June 2025, this innovative program uses a collaborative tumor board style review process to accelerate approvals for companies aligned with critical U.S. national health priorities.

On October 16, 2025, FDA Awards First-Ever National Priority Vouchers to Nine Sponsors. The following 9 products were selected:

• Pergoveris for infertility
• Teplizumab for Type I diabetes
• Cytisinicline for nicotine vaping addiction
• DB-OTO for deafness
• Cenegermin-bkbj for blindness
• RMC-6236 for pancreatic cancer
• Bitopertin for porphyria
• Ketamine for domestic manufacturing of a critical drug for general anesthesia
• Augmentin XR for domestic manufacturing of a common antibiotic 

On November 06, 2025, FDA Awards Second Batch of National Priority Vouchers. The following 6 products were selected following external applications and internal nominations from FDA review divisions:

• Zongertinib for HER2 lung cancer
• Bedaquiline for drug-resistant tuberculosis in young children
• Dostarlimab for rectal cancer
• Casgevy for sickle cell disease
• Orforglipron for obesity and related health conditions
• Wegovy for obesity and related health conditions

The new voucher program was criticized in this NEJM article “Flaws in the FDA’s New Priority Voucher Program” by Carpenter, Hwang, and Kesselheim. The authors argue that while the program seeks to promote innovation and address public health needs, it has significant shortcomings. They note that regulatory review already represents a small portion of total drug-development time and that past voucher programs have shown little evidence of spurring innovation while straining FDA resources. The paper warns that the CNPV program, created without congressional authorization and with vague eligibility criteria, risks politicizing FDA decisions, fostering conflicts of interest, and undermining public trust. Moreover, the compressed review timelines could compromise drug safety and overburden staff. The authors suggest that if implemented, the program should focus on generic drugs where expedited review could have tangible benefits, and should incorporate strong transparency, conflict-of-interest safeguards, and legislative oversight to maintain the integrity of the FDA’s regulatory process.

In a previous post, the FDA's Priority Review Voucher (PRV) programs were discussed. Here’s a side-by-side comparison table summarizing the key similarities and differences between the Commissioner’s National Priority Voucher (CNPV) and the Priority Review Voucher (PRV) programs such as the Rare Pediatric Disease PRV:

Feature	Commissioner’s National Priority Voucher (CNPV)	Priority Review Voucher (PRV) – e.g., Rare Pediatric Disease
Origin / Authorization	Created by the FDA Commissioner in 2025 as a pilot program without explicit congressional authorization.	Created by Congress through legislative action (e.g., the 2012 FDA Safety and Innovation Act for rare pediatric diseases).
Purpose	To accelerate review for drugs aligned with U.S. national health priorities, including unmet needs, national security, innovation, and affordability.	To incentivize development of drugs for neglected or rare conditions (e.g., tropical or rare pediatric diseases).
Review Time Benefit	Shortens FDA review time for selected drugs to 1–2 months, much faster than any existing program.	Converts a standard 10-month review to a priority 6-month review for another drug application.
Eligibility Criteria	Broad and somewhat opaque—drugs must align with “national priorities,” such as public health crises or domestic manufacturing.	Clearly defined by statute—applies to drugs for designated rare pediatric diseases (or other legislatively defined conditions).
Voucher Transferability	Nontransferable (can only be used by the same sponsor; valid if company ownership changes).	Transferable—can be sold or traded to another company, often for hundreds of millions of dollars.
Voucher Expiration	Expires after 2 years if unused.	Does not expire.
Selection and Oversight	Controlled by the FDA Commissioner’s office, raising concerns about political influence and conflicts of interest.	Statutory oversight and criteria limit discretion; implementation and tracking are agency-administered but legislatively mandated.
Scope / Eligible Products	Focused on drugs supporting U.S. national interests (innovation, security, affordability).	Focused on drugs addressing specific rare or neglected diseases.
Impact on FDA Workload	Could significantly burden FDA staff due to extremely short review timelines and unfunded mandates.	Adds workload but within a manageable 6-month priority window, and user fees help fund FDA resources.
Pilot Structure / Limits	Initially limited to five awardees in the first year; long-term limits unclear.	Ongoing statutory program with defined eligibility and reporting mechanisms.
Evidence of Effectiveness	No evidence yet; experts predict limited impact on overall development time and potential risks to review quality.	Empirical studies show limited evidence of incentivizing innovation but measurable market and financial impacts.
Key Concerns	Politicization, conflicts of interest, safety risks from rushed reviews, lack of transparency, and legal vulnerability due to lack of statutory basis.	Limited innovation incentive, windfall profits for some sponsors, and added workload, but more transparent and regulated.
Suggested Improvements	Apply to generic drugs, establish clear criteria, ensure independent review, legislative authorization, and transparency.	Better alignment between voucher incentives and public health impact; continue to monitor postmarket safety.

While both CNPV and PRV programs aim to accelerate access to important therapies, the CNPV is a politically driven, non-statutory pilot emphasizing national priorities, with potentially risky acceleration timelines and limited oversight. In contrast, the PRV system—though imperfect—has a clear legislative framework, defined eligibility, and established oversight mechanisms that maintain greater regulatory transparency and accountability.

FDA's Priority Review Voucher for COVID-19 Vaccine

 To spur drug development in the under-developed area, FDA relies on various policies and programs to incentify the biotech and pharmaceutical companies. The most famous one is the orphan drug development. In the last 10 years or so, a program called 'priority review voucher' become popular. If the biotech and pharmaceutical companies develop a drug in certain underdeveloped areas, once the drug is approved (not emergency user authorization), FDA will issue the marketing authorization holder a priority review voucher. The priority review voucher can be redeemed for future NDA/BLA applications to shorten the review time by four months. The priority review voucher can be a commodity to be sold or transferred to another company for monetary gain. 

• FDA's Priority Review Voucher Programs

• RAPS: Regulatory Explainer: Everything You Need to Know About FDA’s Priority Review Vouchers
• Endpoints: Priority review voucher updates: Who's won PRVs, who's bought them, and how much they're selling for

FDA currently has three priority review voucher programs and each has its own guidance to industries:

• Tropical Disease Priority Review Voucher Program and its guidance
• Rare Pediatric Disease Priority Review Vouchers
• Material Threat Medical Countermeasure Priority Review Vouchers 

To qualify for a PRV for tropical disease, a sponsor’s application must be for a drug or biological product for the prevention or treatment of a “tropical disease,” where a list of tropical diseases are listed by FDA and additional tropical diseases may be added by FDA. For example, Ebola was not in the original list but was added in 2019.

To qualify for a PRV for rare pediatric disease, a sponsor's application must be for a drug or biological product for the prevention or treatment of a "rare pediatric disease," where the rare pediatric disease is defined as:

The 21st Century CuresAct (Cures Act) Section 565A of the FD&C Act was designed to encourage development of new drug and biological medical countermeasures (MCMs), by offering additional incentives for obtaining FDA approval of certain MCMs. While there are existing incentive programs to encourage the development and study of drugs and biologics that may also be applicable to MCMs, section 565A of the FD&C Act provides an incentive specifically for development of certain MCMs, which may be used alone or in some cases in combination with other incentive programs. Other FDA incentive programs include: orphan-drug designation and the associated benefits under the Orphan Drug Act for rare disease drugs; programs to encourage study of drugs used in pediatric populations; various programs to facilitate and expedite development and review of new drugs to address unmet medical needs in the treatment of serious or life-threatening conditions; and programs for certain tropical disease products and antibacterial products. 

Last week (Jan 31, 2022), Moderna obtained the final approval (not emergency user authorization) for its Covid-19. After the approval, a brand drug name or proprietary name - SPIKEVAX - is approved. In the approval letter, FDA granted Moderna a material threat medical countermeasure priority review voucher (PRV).

Endpoints had an article "Exclusive: The curious case of the BioNTech priority review voucher" indicating that for Pfizer/BioNTech's Covid-19 vaccine (brand name Comirnaty) approval, the priority review voucher was not included at the time of the BLA approval. After the approval, BioNTech (as the market authorization holder) received a MCM priority review voucher even though the company did not announce it publicly. 

A priority review voucher can be worth hundreds of millions if transferred. however, the monetary awards from the MCM priority review voucher are trivial compared to the sales of the Covid-19 vaccines - PRV is just a nice-to-have incentive.